Literature DB >> 29684164

Acute kidney injury after aortic valve replacement in a nationally representative cohort in the USA.

Nilay Kumar1, Neetika Garg2.   

Abstract

Background: Randomized trials have consistently shown lower rates of acute kidney injury (AKI) with transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR). Comparative rates of AKI for TAVR versus SAVR, and predictors and prognostic implications of AKI after aortic valve replacement (AVR) have not been well studied in nationally representative real-world data.
Objectives: First, to compare rates of AKI and dialysis requiring AKI in TAVR versus SAVR. Second, to determine predictors of AKI and prognostic implications of AKI in patients undergoing TAVR or SAVR.
Methods: We used the 2011-14 National Inpatient Sample to identify all patients undergoing isolated TAVR or SAVR using validated international classification of diseases, ninth revision ICD-9 codes. Rates of AKI and AKI requiring dialysis (AKI-D) were compared between the two groups using a propensity-matched design. Predictors of AKI and prognostic impact of AKI on in-hospital outcomes were ascertained using multivariate logistic regression.
Results: A total of 8004 unweighted TAVR procedures and 29 355 unweighted SAVR procedures representative of 39 898 TAVR and 143 608 SAVR procedures nationwide were included in the analysis. Mean age of all patients undergoing AVR was 70.9 years and 42.3% were females. In a propensity-matched cohort of 4889 pairs of TAVR and SAVR procedures, TAVR was associated with significantly lower rates of AKI [odds ratio (OR) 0.73, 95% confidence interval (CI) 0.66-0.80, P < 0.001] and AKI-D (OR 0.69, 95% CI 0.50-0.96, P = 0.03) compared with SAVR. AKI was associated with significantly higher rates of in-hospital mortality for TAVR (OR 7.16, 95% CI 5.52-9.29, P < 0.001) as well as SAVR (OR 9.43, 95% CI 7.71-11.55, P < 0.001). Conclusions: In a large propensity-matched cohort of TAVR and SAVR procedures, TAVR was associated with significantly lower rates of AKI and AKI-D compared with SAVR. AKI and AKI-D are predictors of poor in-hospital outcomes in TAVR as well as SAVR.

Entities:  

Mesh:

Year:  2019        PMID: 29684164     DOI: 10.1093/ndt/gfy097

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Propensity matched comparison of TAVI and SAVR in intermediate-risk patients with severe aortic stenosis and moderate-to-severe chronic kidney disease: a subgroup analysis from the German Aortic Valve Registry.

Authors:  Stephan Fichtlscherer; Thomas Walther; Silvia Mas-Peiro; Gloria Faerber; Dimitra Bon; Eva Herrmann; Timm Bauer; Sabine Bleiziffer; Raffi Bekeredjian; Andreas Böning; Christian Frerker; Andreas Beckmann; Helge Möllmann; Stephan Ensminger; Christian W Hamm; Friedhelm Beyersdorf
Journal:  Clin Res Cardiol       Date:  2022-09-08       Impact factor: 6.138

2.  Meta-Analysis Comparing Renal Outcomes after Transcatheter versus Surgical Aortic Valve Replacement.

Authors:  Kuldeep Shah; Zakeih Chaker; Tatiana Busu; Rishita Shah; Mohammed Osman; Fahad Alqahtani; Mohamad Alkhouli
Journal:  J Interv Cardiol       Date:  2019-04-24       Impact factor: 2.279

3.  Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: A US nationwide study.

Authors:  Muhammad Zia Khan; Salman Zahid; Muhammad U Khan; Asim Kichloo; Waqas Ullah; Yasar Sattar; Muhammad Bilal Munir; Atul Singla; Andrew M Goldsweig; Sudarshan Balla
Journal:  Catheter Cardiovasc Interv       Date:  2021-06-19       Impact factor: 2.692

4.  Non-contrast transoesophageal echo-guided transapical transcatheter aortic valve replacement: 10-year experience of a renoprotective strategy.

Authors:  Victor X Mosquera; Alberto Bouzas-Mosquera; Yago Vilela-González; Bárbara Oujo-González; Carlos Velasco-García; José J Cuenca-Castillo; José M Herrera-Noreña
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.